Allergen immunotherapy: Therapeutic vaccines for allergic diseases

Annals of Allergy, Asthma and Immunology

Volumn 81, Issue 5 I, 1998, Pages 401-405

  Bousquet, J ^a   Lockey, R ^a   Mailing, H J ^a   Alvarez Cuesta, E ^a   Canonica, G W ^a   Chapman, M D ^a   Creticos, P J ^a   Dayer, J M ^a   Durham, S R ^a   Demoly, P ^a   Goldstein, R J ^a   Ishikawa, T ^a   Ito, K ^a   Kraft, D ^a   Lambert, P H ^a   Lowenstein H ^a   Muller U ^a   Norman, P S ^a   Reisman, R E ^a   Valenta, R ^a   Valovirta, E ^a   Yssel, H ^a   more..

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; ANTIHISTAMINIC AGENT; CD8 ANTIGEN; CYTOKINE; HAPTEN; HYMENOPTERA VENOM; IMMUNOGLOBULIN E ANTIBODY; MONOCLONAL ANTIBODY; PLASMID DNA; VACCINE; VENOM;

ALLERGIC DISEASE; ALLERGIC RHINITIS; ANAPHYLAXIS; ASTHMA; CLINICAL TRIAL; DERMATOPHAGOIDES PTERONYSSINUS; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; GRASS POLLEN; HUMAN; IMMUNOTHERAPY; INTRANASAL DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PATIENT SELECTION; POLLEN ALLERGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RAGWEED POLLEN; REVIEW; SKIN TEST; STANDARDIZATION; SUBCUTANEOUS DRUG ADMINISTRATION; SUBLINGUAL DRUG ADMINISTRATION; T LYMPHOCYTE;

EID: 2442648797     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)63136-5     Document Type: Article

References (57)

1. Noon L. Prophylactic inoculation against hay fever. Lancet 1911;1: 1572-1573.
2. Bousquet J, Müller UR, Dreborg S, et al. Immunotherapy with Hymenoptera venoms. Position paper of the Working Group on Immunotherapy of the European Academy of Allergy and Clinical Immunology. Allergy 1987;42: 401-413.
3. The current status of allergen immunotherapy (hyposensitisation). Report of a WHO/IUIS working group. Allergy 1989;44:369-379.
4. Current status of allergen immunotherapy. Shortened version of a World Health Organization/International Union of Immunological Societies Working Group Report. Lancet 1989; 1:259-261.
5. Mailing H, Weeke B. Immunotherapy. Position Paper of the European Academy of Allergy and Clinical Immunology. Allergy 1993;48,(Suppl)14:9-35.
6. Muller U, Mosbech H. Position paper: immunotherapy with Hymenoptera venoms. Allergy 1993;48(Suppl)14: 37-46.
7. International Consensus Report on Diagnosis and Management of Asthma. International Asthma Management Project. Allergy 1992;47:1-61.
8. Global strategy for asthma management and prevention. WHO/NHLBI workshop report. In: National Institutes of Health, National Heart, Lung and Blood Institute, Publication Number 95-3659, 1995.
9. International Consensus Report on the Diagnosis and Management of Rhinitis. Allergy 1994;49,(Suppl) 19:1-33.
10. Frew AJ. Injection immunotherapy. British Society for Allergy and Clinical Immunology Working Party. Br Med J 1993;307:919-923.
11. Nicklas R, Bernstein I, Blessing-Moore J, et al. Practice parameters for allergen immunotherapy. J Allergy Clin Immunol 1996;6:1001-1011.
12. Creticos P, Lockey R. Immunotherapy practice. Guide to current procedures. American Academy of Allergy, Asthma & Immunology, Milwaukee, Wisconsin 1994;1-77.
13. Dreborg S, Frew A. Allergen standardization and skin tests. EAACI Position Paper. Allergy 1993;48, suppl 14.
14. The use of standardized allergen extracts. Position Statement. American Academy of Allergy, Asthma and Immunology (AAAAI). J Allergy Clin Immunol 1997;99:583-586.
15. Nelson HS, Ikle D, Buchmeier A. Studies of allergen extract stability: the effects of dilution and mixing. J Allergy Clin Immunol 1996;98:382-388.
16. Norman PS, Lichtenstein LM. The clinical and immunologie specificity of immunotherapy. J Allergy Clin Immunol 1978;61:370-377.
17. Golden DB, Meyers DA, Kagey-Sobotka A, et al. Clinical relevance of the venom-specific immunoglobulin G antibody level during immunotherapy. J Allergy Clin Immunol 1982;69: 489-493.
18. Van-der-Zee JS, Aalberse RC. The role of IgG in immediate-type hypersensitivity. Eur Respir J 1991; 13(Suppl):91s-96s.
19. Varney VA, Hamid QA, Gaga M, et al. Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. J Clin Invest 1993;92: 644-651.
20. Secrist H, Chelen CJ, Wen Y, et al. Allergen immunotherapy decreases interleukin 4 production in CD4+ T cells from allergic individuals. J Exp Med 1993;178:2123-2130.
21. Jutel M, Pichler WJ, Skrbic D, et al. Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-gamma secretion in specific allergen-stimulated T cell cultures. J Immunol 1995;154:4187-4194.
22. Hedlin G, Silber G, Naclerio R, et al. Comparison of the in-vivo and in-vitro response to ragweed immunotherapy in children and adults with ragweed-induced rhinitis. Clin Exp Allergy 1990;20:491-500.
23. Bousquet J, Becker WM, Hejjaoui A, et al. Differences in clinical and immunologie reactivity of patients allergic to grass pollens and to multiple-pollen species. II. Efficacy of a double-blind, placebo-controlled, specific immunotherapy with standardized extracts. J Allergy Clin Immunol 1991;88:43-53.
24. Muller U, Helbling A, Berchtold E. Immunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safety. J Allergy Clin Immunol 1992;89:529-535.
25. Bousquet J, Michel FB. Specific immunotherapy in asthma: is it effective? J Allergy Clin Immunol 1994;94:1-11.
26. Alvarez-Cuesta E, Cuesta-Herranz J, Puyana-Ruiz J, et al. Monoclonal antibody-standardized cat extract immunotherapy: risk-benefit effects from a double-blind placebo study. J Allergy Clin Immunol 1994;93: 556-566.
27. Horst M, Hejjaoui A, Horst V, et al. Double-blind, placebo-controlled rush immunotherapy with a standardized Alternaria extract. J Allergy Clin Immunol 1990;85:460-472.
28. Mailing HJ, Dreborg S, Weeke B. Diagnosis and immunotherapy of mould allergy. V. Clinical efficacy and side effects of immunotherapy with Cladosporium herbarum. Allergy 1986; 41:507-519.
29. Abramson MJ, Puy RM, Weiner JM. Is allergen immunotherapy effective in asthma? A meta-analysis of randomized controlled trials [see comments]. Am J Respir Crit Care Med 1995;151: 969-974.
30. Van-Metre TE J, Adkinson N Jr, Lichtenstein LM, et al. A controlled study of the effectiveness of the Rinkel method of immunotherapy for ragweed pollen hay fever. J Allergy Clin Immunol 1980;65:288-297.
31. Bousquet J, Des-Roches A, Paradis L, et al. Specific immunotherapy in house dust mite allergy. Clin Rev Allergy Immunol 1995;13:151-159.
32. Carreira J, Lombardero M, Ventas P. New developments in in vitro methods. Quantification of clinically relevant allergens in mass units. Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M 1994;87:155-164.
33. Creticos PS, Van-Metre TE, Mardiney MR, et al. Dose response of IgE and IgG antibodies during ragweed immunotherapy. J Allergy Clin Immunol 1984;73:94-104.
34. Haugaard L, Dahl R, Jacobsen L. A controlled dose-response study of immunotherapy with standardized, partially purified extract of house dust mite: clinical efficacy and side effects. J Allergy Clin Immunol 1993;91: 709-722.
35. Olaguibel J, Tabar A, Garcia-Figueroa B, Cortes C. Immunotherapy with standardized extract of Dermatophagoides pteronyssinus in bronchial asthma: a dose-titration study. Allergy 1997;52:in press.
36. Van-Metre TE J, Marsh DG, Adkinson N Jr, et al. Immunotherapy for cat asthma. J Allergy Clin Immunol 1988; 82:1055-1068.
37. Creticos PS, Marsh DG, Proud D, et al. Responses to ragweed-pollen nasal challenge before and after immunotherapy. J Allergy Clin Immunol 1989; 84:197-205.
38. Van-Metre TE J, Adkinson N Jr, Amodio FJ, et al. A comparison of immunotherapy schedules for injection treatment of ragweed pollen hay fever. J Allergy Clin Immunol 1982;69: 181-193.
39. Creticos PS, Reed CE, Norman PS, et al. Ragweed immunotherapy in adult asthma. N Engl J Med 1996;334: 501-506.
40. Hunt KJ, Valentine MD, Sobotka AK, et al. A controlled trial of immunotherapy in insect hypersensitivity. N Engl J Med 1978;299:157-161.
41. Ownby DR, Adinoff AD. The appropriate use of skin testing and allergen immunotherapy in young children [see comments]. J Allergy Clin Immunol 1994;94:662-665.
42. Lockey RF, Benedict LM, Turkeltaub PC, Bukantz SC. Fatalities from immunotherapy (IT) and skin testing (ST). J Allergy Clin Immunol 1987;79: 660-677.
43. Lockey RF, Turkeltaub PC, Olive ES, et al. The Hymenoptera venom study. III. Safety of venom immunotherapy. J Allergy Clin Immunol 1990;86: 775-780.
44. Stewart GD, Lockey RF. Systemic reactions from allergen immunotherapy. J Allergy Clin Immunol 1992;90: 567-578.
45. Lüderitz-Püchel U, May S, Haustein D. Zwischenfalle nach Hyposensibilisierung. Munch med Wschr 1996; 138:129-132.
46. Committee on Safety of Medicines. Desensitizing vaccines. Br Med J 1986;293:948.
47. Bousquet J, Hejjaoui A, Dhivert H, et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. III. Systemic reactions during the rush protocol in patients suffering from asthma. J Allergy Clin Immunol 1989;83:797-802.
48. Norman P. Is there a role for immunotherapy in the treatment of asthma? Yes. Am J Respir Crit Care Med 1996; 154:1225-1228.
49. Barnes P. Is there a role for immunotherapy in the treatment of asthma? No. Am J Respir Crit Care Med 1996; 154:1227-1228.
50. Munir AK, Bjorksten B, Einarsson R, et al. Cat (Fel d I), dog (Can f I), and cockroach allergens in homes of asthmatic children from three climatic zones in Sweden. Allergy 1994;49: 508-516.
51. Mailing H. Local immunotherapy. EAACI-ESPACI Position Paper. Allergy 1997;in press.
52. Ferreira F, Hirthenlehner K, Briza P, et al. Isoforms of atopic allergens with reduced allergenicity but conserved T cell antigenicity: possible use for specific immunotherapy. Int Arch Allergy Immunol 1997;113:125-127.
53. Yssel H, Fasler S, Lamb J, de-Vries JE. Induction of non-responsiveness in human allergen-specific type 2 T helper cells. Curr Opin Immunol 1994; 6:847-852.
54. Ball T, Vrtala S, Sperr WR, et al. Isolation of an immunodominant IgE hapten from an epitope expression cDNA library. Dissection of the allergic effector reaction. J Biol Chem 1994;269: 28323-28328.
55. Visco V, Dolecek C, Denepoux S, et al. Human IgG monoclonal antibodies that modulate the binding of specific IgE to birch pollen Bet v1. J Immunol 1996;157:956-962.
56. Lebecque S, Dolecek C, Laffler S, et al. Immunologie characteristization of monoclonal antibodies which modulate human immunoglobulin E binding to the major birch pollen allergen Bet v1. J Allergy Clin Immunol 1997;99: 374-384.
57. Raz E, Tighe H, Sato Y, et al. Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization. Proc Natl Acad Sci USA 1996;93:5141-5145.